Empagliflozin, Sitagliptin and Metformin Tablets: Uses, Benefits & Price in India | Steris Healthcare You're using the free version of ChatGPT. Upgrade for advanced models, better memory, and higher-quality image creation. Try Plus free

What Are Empagliflozin, Sitagliptin and Metformin Hydrochloride Tablets Used For?

Empagliflozin, sitagliptin and metformin hydrochloride tablets are a prescription combination medicine intended to help manage blood glucose levels in appropriately selected adults with type 2 diabetes mellitus. The three active ingredients act through different biological pathways, helping improve glucose regulation when treatment with multiple medicines is clinically appropriate.

How Does Gliempaflozin 3D Work?

The three ingredients have complementary mechanisms of action.

1. Empagliflozin: Helps the kidneys remove glucose

Empagliflozin belongs to the sodium-glucose cotransporter 2 (SGLT2) inhibitor class. It reduces glucose reabsorption in the kidneys, allowing more glucose to leave the body through urine.

Its glucose-lowering action is not directly dependent on stimulating insulin secretion. However, it can increase urination and contribute to dehydration or genital fungal infections in some people. Empagliflozin also has established cardiovascular and kidney benefits in specific patient populations and indications; these benefits should not automatically be attributed to every fixed-dose combination.

2. Sitagliptin: Supports glucose-dependent insulin regulation

Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. It increases the activity of incretin hormones, which help the pancreas release insulin when blood glucose is elevated and reduce inappropriate glucagon secretion.

This mechanism helps regulate blood glucose, particularly after meals. Sitagliptin generally has a low risk of hypoglycaemia when used alone, although the risk increases when combined with insulin or sulfonylureas.

3. Metformin hydrochloride ER: Reduces glucose production

Metformin is a biguanide antidiabetic medicine. It primarily reduces glucose production by the liver and improves the body's response to insulin. The extended-release formulation is designed to release the medicine over a longer period.

Metformin commonly causes gastrointestinal effects, particularly during treatment initiation or dose escalation. Kidney function must be assessed because impaired renal clearance can increase the risk of a rare but serious complication called lactic acidosis.

Key Benefits of Empagliflozin, Sitagliptin and Metformin Hydrochloride

When prescribed appropriately, this triple combination may offer the following treatment-related benefits.

Multiple pathways for blood glucose control

The combination targets glucose reabsorption by the kidneys, incretin-related hormone regulation and hepatic glucose production. Using complementary mechanisms may help improve blood glucose control in patients who require all three medicines.

Support for HbA1c management

HbA1c reflects average blood glucose over approximately two to three months. By acting through different pathways, the three medicines can contribute to better HbA1c control. The actual response varies with baseline HbA1c, adherence, diet, physical activity, kidney function and other prescribed treatments.

Potential convenience of combination therapy

A fixed-dose tablet can reduce the number of separate tablets a patient needs to take compared with the same ingredients prescribed individually. However, convenience does not make the combination suitable for everyone, and a fixed-dose formulation may be less flexible when an individual ingredient needs adjustment.

Potential weight-related benefit

Empagliflozin can contribute to modest weight reduction in some patients because glucose is lost through urine. Metformin is generally weight-neutral or may support modest weight reduction. Individual responses differ, and this medicine should not be used solely for weight loss.

Complementary action after meals and between meals

Sitagliptin supports glucose-dependent hormonal responses, while metformin reduces hepatic glucose production and empagliflozin increases urinary glucose excretion. Together, these actions may help address different contributors to elevated blood glucose.

Indications: Who May Be Prescribed This Combination?

A clinician may consider empagliflozin, sitagliptin and metformin hydrochloride for an adult with type 2 diabetes who needs additional glucose-lowering treatment and is suitable for all three ingredients.

Potential clinical considerations include:

• Blood glucose or HbA1c remaining above the individual's treatment target.

• The patient's response to previous antidiabetic medicines.

• Whether the three active ingredients are appropriate together.

• Renal function and risk of dehydration.

• History of pancreatitis, recurrent genital infections or other relevant adverse effects.

• Other medicines, including insulin, sulfonylureas and diuretics.

Gliempaflozin 3D 10 vs Gliempaflozin 3D 25

The main listed difference is the empagliflozin strength.

Gliempaflozin 3D 10 contains empagliflozin 10 mg alongside sitagliptin 100 mg and metformin hydrochloride ER 1000 mg.

Gliempaflozin 3D 25 contains empagliflozin 25 mg alongside sitagliptin 100 mg and metformin hydrochloride ER 1000 mg.

Dosage and Administration Guidelines

The dose must be prescribed according to the patient's current treatment, glucose control, kidney function and the approved product label.

• Take the medicine exactly as directed by the treating clinician.

• Follow the label's instructions regarding meals and timing.

• Swallow extended-release tablets as instructed; do not crush or chew them unless the approved product information specifically permits it.

• Do not take an extra tablet to compensate for a missed dose without following the prescribed instructions.

• Do not double the dose after a missed dose.

• Continue recommended diet, physical activity and glucose monitoring.

Side Effects of Empagliflozin, Sitagliptin and Metformin Hydrochloride

Possible side effects include:

• Nausea or stomach discomfort.

• Diarrhoea or loose stools.

• Abdominal discomfort.

• Increased urination.

• Genital fungal infections.

• Urinary tract symptoms.

• Dehydration, dizziness or low blood pressure.

• Headache or other nonspecific symptoms.

Serious side effects requiring prompt medical attention

Diabetic ketoacidosis: Empagliflozin can be associated with ketoacidosis, sometimes even when blood glucose is not markedly elevated. Warning symptoms include nausea, vomiting, abdominal pain, unusual tiredness and difficulty breathing.

Lactic acidosis: Metformin can rarely cause a serious buildup of lactic acid, particularly in people with significant renal impairment or certain acute illnesses. Severe weakness, unusual sleepiness, abdominal symptoms or breathing difficulties require urgent assessment.

Pancreatitis: Sitagliptin has been associated with reports of acute pancreatitis. Seek medical care for persistent, severe abdominal pain, especially if it spreads to the back or occurs with vomiting.

Severe dehydration or infection: Seek urgent assessment for fainting, severe dizziness, fever with urinary symptoms or rapidly worsening illness.

Allergic reactions: Swelling of the face or throat, difficulty breathing or a severe widespread reaction requires emergency care.

Precautions and Warnings

Kidney function

Renal function should be assessed before treatment and monitored as clinically appropriate. Kidney impairment can affect the suitability of metformin and may require sitagliptin dose adjustment if prescribed separately. Empagliflozin's glucose-lowering effect also changes with kidney function.

Dehydration and low blood pressure

People taking diuretics, those with low blood pressure, and those who are elderly or prone to dehydration may need additional monitoring. Maintain appropriate hydration unless a clinician has prescribed fluid restriction.

Surgery, fasting and acute illness

Tell the healthcare professional about empagliflozin use before surgery or procedures involving prolonged fasting. SGLT2 inhibitors may need to be withheld before certain procedures according to the applicable prescribing information. Do not independently decide when to stop or restart the medicine.

During vomiting, severe diarrhoea, inability to eat or drink, or serious acute illness, seek medical advice promptly because dehydration, kidney injury and ketoacidosis risks may increase.

Pregnancy and breastfeeding

If you are pregnant, planning pregnancy or breastfeeding, discuss diabetes treatment with your clinician. This combination may not be suitable, and treatment should be reviewed individually.

Other medicines

Inform your prescriber about insulin, sulfonylureas, diuretics, other glucose-lowering medicines, alcohol use and any medicines that may affect kidney function. Combining treatments may increase the risk of hypoglycaemia or other complications.

Efficacy and Clinical Evidence

Clinical evidence for the three individual medicines supports their distinct glucose-lowering mechanisms. Evidence from studies of a fixed-dose triple combination should be interpreted according to the study design and the population studied.

A 2026 multicentre, retrospective observational study reported real-world prescribing patterns among 12,843 Indian adults with type 2 diabetes receiving empagliflozin, sitagliptin and metformin fixed-dose combinations. The study included patients receiving empagliflozin 10 mg or 25 mg, sitagliptin 100 mg and metformin 1000 mg. It described patient characteristics and glucose measurements across treatment groups. Because the study was observational, differences between groups do not establish that one strength is superior or that the treatment caused the observed differences. https://pubmed.ncbi.nlm.nih.gov/42774963/

For an accurate assessment of efficacy, clinicians consider HbA1c changes, fasting and post-meal glucose, adverse effects, renal function, adherence and relevant cardiovascular or kidney outcomes. Evidence for an individual ingredient should not be presented as proof that every combination product provides the same outcome in every patient.

What patients should understand about efficacy

• Treatment response differs between individuals.

• HbA1c and glucose monitoring help assess effectiveness.

• The prescribed dose should not be increased without clinical review.

• A medicine's potential benefits must be balanced against its risks and contraindications.

• No fixed-dose combination can guarantee normal blood glucose or prevent all diabetes complications.

Why Choose Gliempaflozin 3D from Steris Healthcare?

Gliempaflozin 3D 10 and Gliempaflozin 3D 25 are listed in the Steris Healthcare product range for the management of type 2 diabetes.

For healthcare professionals, pharmacists and medicine purchasers, relevant product checks include:

• Confirming the exact active ingredients and strengths.

• Checking the approved formulation and pack information.

• Verifying the batch number, expiry date and product integrity.

• Purchasing through an authorised and appropriate supply channel.

• Following prescription requirements and storage instructions.

Conclusion

Empagliflozin, sitagliptin and metformin hydrochloride combine three glucose-lowering mechanisms to help manage type 2 diabetes in appropriately selected patients. Gliempaflozin 3D 10 and Gliempaflozin 3D 25 differ primarily in their listed empagliflozin strengths, while both include sitagliptin 100 mg and metformin hydrochloride ER 1000 mg.

The right treatment depends on glucose control, kidney function, medical history, tolerability and professional assessment. Patients should follow their prescription, monitor glucose as advised and seek medical attention for serious warning symptoms.

Steris Healthcare Pvt. Ltd. provides product information for Gliempaflozin 3D 10 and Gliempaflozin 3D 25. Contact the company for verified composition, pack details and availability.